Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
727
Completed, industry sponsors, Immunology and inflammation, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting150
- Completed727
727 trials
Showing 1 to 25, recently updated first.
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06846710 · 60 participants · Start May 2, 2025 · Primary completion Jul 14, 2026
Drug: HS-20118 · For: Psoriasis
Sites: Anaheim, California; Miami Lakes, Florida; Pompano Beach, Florida · 9 sites in all
Arxx TherapeuticsIndustry
NCT05965089 · 57 participants · Start Apr 25, 2023 · Primary completion Jul 31, 2024
Drug: Placebo; AX-202 · For: Healthy Volunteers; Mild to Moderate Psoriasis
Sites: Manchester, United Kingdom
AltruBio Inc.Industry
NCT07350577 · 24 participants · Start Nov 17, 2025 · Primary completion Apr 6, 2026
Drug: ALTB-268 · For: Ulcerative Colitis (UC)
Sites: Miami, Florida
- A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative ColitisCompleted
Accro Bioscience (Suzhou) LimitedIndustry
NCT07083193 · 25 participants · Start Jan 20, 2025 · Primary completion Apr 20, 2026
Drug: AC-101 · For: Ulcerative Colitis
Sites: Guangzhou, China
- A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy ParticipantsPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT06268860 · 240 participants · Start Feb 15, 2024 · Primary completion Aug 30, 2024
Drug: Rocatinlimab vial injection · For: Atopic Dermatitis
Sites: Daytona Beach, Florida; Dallas, Texas; Madison, Wisconsin · 4 sites in all
- Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy VolunteersPivotal-lookingCompleted
Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
NCT07254325 · 114 participants · Start Dec 15, 2025 · Primary completion Jun 12, 2026
Drug: Secukinumab 150mg s.c. · For: Psoriasis
Sites: Shanghai, China
Novartis PharmaceuticalsNovartis (NVS)
NCT05798117 · 21 participants · Start Feb 28, 2023 · Primary completion Sep 24, 2026
Drug: YTB323 · For: Systemic Lupus Erythematosus; Lupus Nephritis
Sites: Clayton, Australia; Paris, France; Pessac, France · 10 sites in all
- A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous InjectionPivotal-lookingCompleted
Jiangsu Genscend Biopharmaceutical Co., LtdIndustry
NCT07411755 · 294 participants · Start Mar 5, 2026 · Primary completion Aug 8, 2026
Drug: GS101 injection; U.S. commercial Dupixent® and 1 more · For: Atopic Dermatitis (AD)
Sites: Suzhou, China
Toll Biotech Co. Ltd. (Beijing)Industry
NCT06103773 · 98 participants · Start Sep 28, 2023 · Primary completion Apr 7, 2025
Drug: TollB-001 tablets; TollB-001 placebo · For: Rheumatoid Arthritis
Sites: Chengdu, China
NCT07849894 · 54 participants · Start Jun 23, 2017 · Primary completion Dec 8, 2018
Drug: UCB0159 · For: Mild to Moderate Psoriasis; Healthy Volunteers
Sites: Berlin, Germany; Harrow, United Kingdom
Ascletis Pharma (China) Co., LimitedIndustry
NCT07024602 · 55 participants · Start Jun 4, 2025 · Primary completion Jul 1, 2026
Drug: ASC50 tablets or matching placebo · For: Plaque Psoriasis
Sites: Miami, Florida
- A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus ErythematosusPivotal-lookingCompleted
Kyowa Kirin Co., Ltd.Industry
NCT05411016 · 125 participants · Start Aug 3, 2022 · Primary completion Dec 10, 2024
Drug: Placebo; KK4277 · For: Healthy Volunteers; Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)
Sites: Kutsukake, Japan; Minami, Japan; Urayasu, Japan · 23 sites in all
Kangpu Biopharmaceuticals, Ltd.Industry
NCT04643067 · 64 participants · Start Jun 3, 2021 · Primary completion Jun 29, 2023
Drug: KPG-818 low dose in phase 1b; KPG-818 mid dose in phase 1b and 6 more · For: SLE; Drug
Sites: Anniston, Alabama; Birmingham, Alabama; Clearwater, Florida · 18 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT06693908 · 24 participants · Start Mar 31, 2025 · Primary completion Jul 13, 2026
Drug: Vixarelimab · For: Moderate to Severe Ulcerative Colitis
Sites: Berlin, Germany
HK inno.N CorporationIndustry
NCT05729074 · 81 participants · Start Feb 13, 2023 · Primary completion Sep 20, 2024
Drug: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment; IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment and 6 more · For: Mild to Moderate Atopic Dermatitis
Sites: Cheongju-si, South Korea
- Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic DermatitisCompleted
Attovia Therapeutics IncIndustry
NCT07205081 · 48 participants · Start Oct 22, 2025 · Primary completion Aug 13, 2026
Drug: ATTO-3712; Placebo · For: Normal Volunteers; Atopic Dermatitis (AD); Atopic Eczema and 1 more
Sites: Encinitas, California; Fountain Valley, California; Huntington Beach, California · 17 sites in all
- Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic PruritusPivotal-lookingCompleted
Attovia Therapeutics IncIndustry
NCT06787586 · 108 participants · Start Jan 14, 2025 · Primary completion Jun 11, 2026
Drug: ATTO-1310; ATTO-1310 Placebo · For: Normal Volunteers; Atopic Dermatitis (AD); Atopic Eczema and 1 more
Sites: Encinitas, California; Rocklin, California; Sacramento, California · 17 sites in all
PfizerPfizer (PFE)
NCT07190430 · 16 participants · Start Oct 3, 2025 · Primary completion Dec 15, 2025
Drug: PF-08049820; Midazolam and 2 more · For: Atopic Dermatitis
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT07284173 · 18 participants · Start Nov 3, 2025 · Primary completion Dec 18, 2025
Drug: PF-08049820; Rabeprazole · For: Healthy Adults
Sites: Beijing, China · 2 sites in all
Nanjing Immunophage Biotech Co., LtdIndustry
NCT06717815 · 24 participants · Start Feb 25, 2025 · Primary completion Jun 8, 2026
Drug: IPG11406 · For: Lupus Nephritis
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 17 sites in all
PfizerPfizer (PFE)
NCT06686797 · 71 participants · Start Nov 27, 2024 · Primary completion Feb 23, 2026
Drug: PF-08049820; Placebo · For: Healthy
Sites: New Haven, Connecticut
Zenas BioPharma (USA), LLCIndustry
NCT05638854 · 72 participants · Start Dec 8, 2022 · Primary completion Feb 16, 2026
Drug: ZB002; Placebo and 2 more · For: Healthy Volunteers; Rheumatoid Arthritis
Sites: Melbourne, Australia; Christchurch, New Zealand
Noxopharm LimitedIndustry
NCT07072611 · 24 participants · Start Jul 14, 2025 · Primary completion Dec 27, 2025
Drug: SOF-SKN 0.25%; SOF-SKN 0.5% and 3 more · For: Cutaneous Lupus Erythematosus
Sites: Melbourne, Australia
- A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult VolunteersPivotal-lookingCompleted
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.Industry
NCT06082323 · 150 participants · Start Jun 13, 2024 · Primary completion Nov 25, 2025
Drug: LT-002-158/Placebo oral tablet(s) · For: Healthy Volunteer; Hidradenitis Suppurativa; Atopic Dermatitis
Sites: Shanghai, China
- A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy SubjectsPivotal-lookingCompleted
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07264335 · 160 participants · Start Mar 7, 2026 · Primary completion Jun 26, 2026
Drug: SHR-1819 Injection · For: Atopic Dermatitis
Sites: Hefei, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.